Generic drug makers not absolved of liability
U.S. District Judge Berle M. Schiller has ruled that manufacturers of generic drugs are not protected from lawsuits even if the Food and Drug Administration (FDA) certifies them as the “bioequivalent” of their brand name predecessors. The lawsuit involved consumers who were previously taking the brand name antidepressant Wellbutrin.
The defendants allege after switching to a generic version of the drug, buproprion, made by Teva Pharmaceuticals and Impax Laboratories, they experienced side effects. The lawsuit contends Teva and Impax became aware of the side effects but failed to warn consumers. While the active ingredient in Wellbutin and buproprion is the same, the two have differing release rates, which the defendants say caused adverse events when they switched to bupropion.
![[ Beasley Allen Law Firm Logo ]](http://www.southerninjurylawyer.com/wp-content/themes/system-unity/images/logo.png)









